Pediatric Exclusivity-Associated Revenues and Labeling Changes, 2013-2023

Area of Science:

• Pediatric pharmacology
• Drug regulation
• Pharmaceutical economics

Background:

• The Best Pharmaceuticals for Children Act (BPCA) established a pediatric exclusivity provision to incentivize drug development for children.
• Understanding the benefits and costs of this provision is crucial for evaluating its impact on pediatric medicine and market dynamics.

Purpose of the Study:

• To assess the benefits (clinical trials, labeling changes) and costs (delayed generic competition, manufacturer revenues) of the BPCA's pediatric exclusivity provision.
• To analyze data from 2013 to 2023 to quantify the impact of the BPCA.

Main Methods:

• Retrospective cohort study utilizing public FDA and ClinicalTrials.gov data.
• Identification of drugs granted BPCA pediatric exclusivity (2013-2023).
• Evaluation of clinical trials, labeling changes, and revenue data using the SSR Health database for drugs with generic entry.

Main Results:

• 229 clinical trials and 110 pediatric exclusivity grants occurred between 2013-2023.
• 97% of grants resulted in new efficacy labeling; 20% in new safety labeling.
• Median excess revenue was $133.8 million per grant, totaling $9.03 billion, with exclusivity granted a median of 2.34 years before generic entry.

Conclusions:

• The BPCA effectively generates crucial clinical information for pediatric drug labeling.
• The provision significantly increases pharmaceutical manufacturer revenues by extending market exclusivity.
• Potential modifications to the BPCA implementation could enhance the timeliness and cost-effectiveness of acquiring pediatric drug information.